C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Andrew Hirsch, the company's president and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 2:15 PM PST (5:15 PM EST).

The presentation will be accessible via live webcast through C4T's website in the Events & Presentations section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available on the company's website for a minimum of two weeks following the presentation.

News Market Reaction – CCCC

-0.52%

1 alert

-0.52% News Effect

On the day this news was published, CCCC declined 0.52%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST).

The presentation will be webcast live and may be accessed through C4T’s website on the Events & Presentations page. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

FAQ

When is C4 Therapeutics (CCCC) presenting at the 2025 J.P. Morgan Healthcare Conference?

C4 Therapeutics will present on Wednesday, January 15, 2025, at 2:15 PM PST (5:15 PM EST).

How can investors watch C4 Therapeutics' (CCCC) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast through C4T's website on the Events & Presentations page.

How long will C4 Therapeutics' (CCCC) J.P. Morgan presentation replay be available?

The webcast replay will be archived on C4T's website for at least two weeks following the presentation.

Who is presenting for C4 Therapeutics (CCCC) at the 2025 J.P. Morgan Healthcare Conference?

Andrew Hirsch, president and chief executive officer of C4T, will present at the conference.